Observational studyJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2014
Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW).
Observational study in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 57 citations in OpenAlex.
- Frailty Change and Major Osteoporotic Fracture in the Elderly: Data from the Global Longitudinal Study of Osteoporosis in Women 3-Year Hamilton Cohort.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2016Trial
- Comorbidity indices for clinical trials: adaptation of two existing indices for use with the FREEDOM trial in women with postmenopausal osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2016Trial
- Management of postmenopausal osteoporosis.Endocrine reviews · 2026Review
- Osteoporosis documentation following hip fracture: a retrospective cohort study from a tertiary hospital.BMC musculoskeletal disorders · 2026Article
- Pharmacotherapy change patterns after fragility fracture in patients receiving bone-active medication: a fracture liaison service quality improvement cohort study.BMC musculoskeletal disorders · 2026Article
- Effect of comorbidities and multimorbidity on bone mineral density in patients with osteoporosis.Archives of osteoporosis · 2025Article
- What are patients' experiences of discontinuing clozapine and how does this impact their views on subsequent treatment?BMC psychiatry · 2023Article
- New Horizons: Artificial Intelligence Tools for Managing Osteoporosis.The Journal of clinical endocrinology and metabolism · 2023Article
- Comorbidity and osteoporotic fracture: approach through predictive modeling techniques using the OSTEOMED registry.Aging clinical and experimental research · 2022Observational
- Bone mineral density response prediction following osteoporosis treatment using machine learning to aid personalized therapy.Scientific reports · 2021Article
- Factors associated with inadequate responses to risedronate in Japanese patients with osteoporosis.Journal of bone and mineral metabolism · 2019Article
- Observational
- Comparison of Osteoporosis Pharmacotherapy Fracture Rates: Analysis of a MarketScanInternational journal of endocrinology and metabolism · 2018Article
- Secretome analysis of rat osteoblasts during icariin treatment induced osteogenesis.Molecular medicine reports · 2018Article
- Spanish consensus on treat to target for osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2018Article
- Bone Phenotype Assessed by HRpQCT and Associations with Fracture Risk in the GLOW Study.Calcified tissue international · 2018Article
- Flavopiridol Protects Bone Tissue by Attenuating RANKL Induced Osteoclast Formation.Frontiers in pharmacology · 2018Article
- Diversity in fall characteristics hampers effective prevention: the precipitants, the environment, the fall and the injury.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2017Article
- Predictors of teriparatide treatment failure in patients with low bone mass.Bone reports · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 18 institutions in 11 countries.
Funding
Abstract
Antiosteoporosis medication (AOM) does not abolish fracture risk, and some individuals experience multiple fractures while on treatment. Therefore, criteria for treatment failure have recently been defined. Using data from the Global Longitudinal Study of Osteoporosis in Women (GLOW), we analyzed risk factors for treatment failure, defined as sustaining two or more fractures while on AOM. GLOW is a prospective, observational cohort study of women aged ≥55 years sampled from primary care practices in 10 countries. Self-administered questionnaires collected data on patient characteristics, fracture risk factors, previous fractures, AOM use, and health status. Data were analyzed from women who used the same class of AOM continuously over 3 survey years and had data available on fracture occurrence. Multivariable logistic regression was used to identify independent predictors of treatment failure. Data from 26,918 women were available, of whom 5550 were on AOM. During follow-up, 73 of 5550 women in the AOM group (1.3%) and 123 of 21,368 in the non-AOM group (0.6%) reported occurrence of two or more fractures. The following variables were associated with treatment failure: lower Short Form 36 Health Survey (SF-36) score (physical function and vitality) at baseline, higher Fracture Risk Assessment Tool (FRAX) score, falls in the past 12 months, selected comorbid conditions, prior fracture, current use of glucocorticoids, need of arms to assist to standing, and unexplained weight loss ≥10 lb (≥4.5 kg). Three variables remained predictive of treatment failure after multivariable analysis: worse SF-36 vitality score (odds ratio [OR] per 10-point increase, 0.85; 95% confidence interval [CI], 0.76-0.95; p = 0.004); two or more falls in the past year (OR, 2.40; 95% CI, 1.34-4.29; p = 0.011), and prior fracture (OR, 2.93; 95% CI, 1.81-4.75; p < 0.0001). The C statistic for the model was 0.712. Specific strategies for fracture prevention should therefore be developed for this subgroup of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.